Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.

Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalská D, Marin F, Pavo I, Stepan JJ.

Bone. 2014 Feb;59:139-47. doi: 10.1016/j.bone.2013.11.011. Epub 2013 Nov 20.

PMID:
24269280
2.

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.

Hofstetter B, Gamsjaeger S, Varga F, Dobnig H, Stepan JJ, Petto H, Pavo I, Klaushofer K, Paschalis EP.

Osteoporos Int. 2014 Dec;25(12):2709-19. doi: 10.1007/s00198-014-2814-2. Epub 2014 Jul 19.

PMID:
25037600
3.

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.

Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalská D, Pavo I.

Osteoporos Int. 2010 Dec;21(12):2027-36. doi: 10.1007/s00198-009-1168-7. Epub 2010 Feb 5.

PMID:
20135094
4.

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.

Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF.

J Bone Miner Res. 2005 Jul;20(7):1244-53. Epub 2005 Mar 14.

PMID:
15940379
5.

Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.

Ma YL, Marin F, Stepan J, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Martínez G, Malouf J, Zeng QQ, Wan X, Recker RR.

Bone. 2011 May 1;48(5):972-8. doi: 10.1016/j.bone.2011.01.012. Epub 2011 Jan 22.

PMID:
21262402
6.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

PMID:
15068497
7.

Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.

Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB.

J Bone Miner Res. 2007 Apr;22(4):495-502.

PMID:
17227219
8.

A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.

Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW.

J Bone Miner Res. 2006 Mar;21(3):366-73. Epub 2005 Nov 21.

PMID:
16491283
9.

Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP.

Bone. 2011 Dec;49(6):1160-5. doi: 10.1016/j.bone.2011.08.015. Epub 2011 Aug 27.

PMID:
21893225
10.

Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.

Dempster DW, Cosman F, Zhou H, Nieves JW, Bostrom M, Lindsay R.

J Bone Miner Res. 2016 Aug;31(8):1518-26. doi: 10.1002/jbmr.2822. Epub 2016 Mar 21.

PMID:
26916877
11.

Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K, Roschger P.

J Bone Miner Res. 2010 Nov;25(11):2297-303. doi: 10.1002/jbmr.198.

PMID:
20683883
12.

Changes in cortical width with bone turnover in the three different endosteal envelopes of the ilium in postmenopausal osteoporosis.

Tanizawa T, Itoh A, Uchiyama T, Zhang L, Yamamoto N.

Bone. 1999 Oct;25(4):493-9.

PMID:
10511118
13.

Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.

Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R.

J Bone Miner Res. 2014 Mar;29(3):618-28. doi: 10.1002/jbmr.2074.

PMID:
23959630
14.

Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.

Whitmarsh T, Treece GM, Gee AH, Poole KE.

J Bone Miner Res. 2015 Jul;30(7):1309-18. doi: 10.1002/jbmr.2454.

PMID:
25639838
15.

Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis.

Wan X, Zhao Y, Burge R, Jiang Y.

Osteoporos Int. 2013 Dec;24(12):3011-9. doi: 10.1007/s00198-013-2414-6. Epub 2013 Jul 24.

PMID:
23881284
16.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002. Epub 2011 Oct 17.

PMID:
22015818
17.

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.

J Bone Miner Res. 2013 Jun;28(6):1328-36. doi: 10.1002/jbmr.1853.

PMID:
23281041
18.

Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.

Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P.

Bone. 2010 Jan;46(1):41-8. doi: 10.1016/j.bone.2009.09.032. Epub 2009 Oct 1.

PMID:
19800436
19.

Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).

Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K.

J Bone Miner Res. 2010 Jan;25(1):48-55. doi: 10.1359/jbmr.090702.

PMID:
19580465
20.

Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H.

J Bone Miner Res. 2013 Jan;28(1):196-205. doi: 10.1002/jbmr.1716.

PMID:
22836585

Supplemental Content

Support Center